VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Monday, December 29, 2025

Stock Comparison

Novo Nordisk A/S vs Symrise AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Novo Nordisk A/S

NOVOB · Nasdaq Copenhagen

Market cap (USD)$232.3B
SectorHealthcare
CountryDK
Data as of2025-12-28
Moat score
85/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.

View NOVOB analysis

Symrise AG

SY1 · Xetra

Market cap (USD)$14.5B
SectorMaterials
CountryDE
Data as of2025-12-29
Moat score
69/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Symrise AG's moat claims, evidence, and risks.

View SY1 analysis

Comparison highlights

  • Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 69 / 100 for Symrise AG).
  • Segment focus: Novo Nordisk A/S has 3 segments (71.1% in Diabetes care); Symrise AG has 2 segments (61.8% in Taste, Nutrition & Health).
  • Moat breadth: Novo Nordisk A/S has 5 moat types across 3 domains; Symrise AG has 5 across 3.

Primary market context

Novo Nordisk A/S

Diabetes care

Market

Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)

Geography

Global

Customer

Payers/providers and patients (via wholesalers/pharmacies/hospitals)

Role

Originator pharma (R&D, regulatory, manufacturing, commercialization)

Revenue share

71.1%

Symrise AG

Taste, Nutrition & Health

Market

Food & beverage flavor ingredients and pet food ingredients

Geography

Global

Customer

B2B (food & beverage, pet food, aquafeed manufacturers)

Role

Ingredient/formulation supplier

Revenue share

61.8%

Side-by-side metrics

Novo Nordisk A/S
Symrise AG
Ticker / Exchange
NOVOB - Nasdaq Copenhagen
SY1 - Xetra
Market cap (USD)
$232.3B
$14.5B
Sector
Healthcare
Materials
HQ country
DK
DE
Primary segment
Diabetes care
Taste, Nutrition & Health
Market structure
Oligopoly
Oligopoly
Market share
33.7% (reported)
12%-16% (implied)
HHI estimate
n/a
958
Pricing power
Moderate
Moderate
Moat score
85 / 100
69 / 100
Moat domains
Legal, Supply, Demand
Demand, Supply, Legal
Last update
2025-12-28
2025-12-29

Moat coverage

Shared moat types

IP Choke Point

Novo Nordisk A/S strengths

Regulated Standards PipeCapacity MoatBrand TrustLearning Curve Yield

Symrise AG strengths

Design In QualificationPreferential Input AccessScope EconomiesCapex Knowhow Scale

Segment mix

Novo Nordisk A/S segments

Full profile >

Diabetes care

Oligopoly

71.1%

Obesity care

Duopoly

22.4%

Rare disease

Oligopoly

6.4%

Symrise AG segments

Full profile >

Taste, Nutrition & Health

Oligopoly

61.8%

Scent & Care

Oligopoly

38.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.